Conduct Active Post Marketing Surveillance Study: CDSCO Panel tells Novo Nordisk on Somapacitan Injection

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-04-28 12:30 GMT | Update On 2024-04-28 12:30 GMT

New Delhi: Granting approval for waiving off the Phase-IV study, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Novo Nordisk to conduct the Active Post Marketing Surveillance (PMS) study of Somapacitan Injection 5 mg/1.5 ml, 10mg/1.5ml and 15 mg/1.5 ml solution for injection in PFP.

This came after Novo Nordisk presented the proposal for waiver of the Phase-IV clinical study imposed in the marketing authorization permission granted for the drug Somapacitan.

Somapacitan is a long-acting recombinant human growth hormone derivative. Somatropin injection is used to replace growth hormone (a natural hormone produced by your body) in adults and children with growth hormone deficiency. Somatropin injection is also used to increase growth in children with certain conditions that affect normal growth and development.

Somapacitan binds to the growth hormone receptor and induces intracellular signaling to up-regulate insulin-like growth factor I (IGF-1). IGF-1 causes growth in bones and muscle tissue.

At the recent SEC meeting for endocrinology and metabolism held on 10th April 2024, the expert panel reviewed the proposal for waiver of the Phase-IV clinical study imposed in the marketing authorization permission granted for the drug Somapacitan.

After detailed deliberation, the committee agreed to a waiver of the Phase-IV study condition and recommended conducting an Active Post-Marketing Surveillance (PMS) study.

Accordingly, the expert panel suggested that the firm should submit the protocol to conduct an Active PMS study within three months.

Also Read: Eli Lilly Gets CDSCO Panel Nod to Study Lepodisiran

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Conduct Active Post Marketing Surveillance Study: CDSCO Panel tells Novo Nordisk on Somapacitan Injection

Similar News